Signals, Powered By EquityPandit
Aurobindo Pharma has got the US health regulator’s final approval for manufacturing and marketing its anaesthetic Bupivacaine Hydrochloride injection in the American market.
Aurobindo Pharma has said in a BSE filing that the company “has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bupivacaine Hydrochloride injection USP, 0.25 percent (2.5 mg/mL) and 0.5 percent (5mg/mL) 50 mL multiple dose vials.”
It further said that this product is expected to be launched in the second quarter of 2016-17 fiscal.
“The approved product has an estimated market size of USD 5.6 million for the twelve months ended March 2016, according to IMS.”
